Increased C-reactive protein is associated with the severity of thoracic radiotherapy-induced cardiomyopathy

Cardio-Oncology

Table 1 Characteristics of the Cohort

Variables	Median [IQR] or N (%)
Age, years	63 [59–66]
Female, n (%)	15 (60%)
Caucasian, n (%)	16 (64%)
African-American, n (%)	9 (36%)
Body mass index, kg/m²	26.4 [22.6–30.2]
Cancer Type
Lung	15 (60%)
Breast	10 (40%)
Time since Cancer Diagnosis, years	2.4 [1.1–3.9]
Prior chemotherapy	21 (84%)
Time since completion of chemotherapy, years	1.5 [0.5–3.0]
Time since completion of Radiotherapy, years	1.8 [0.4–3.6]
Hormonal modulating therapy (Breast cancer only)	7 (28%)
MCRD, Gy	5.4 [3.7–14.7]
C-reactive protein, mg/L	3.0 [1.7–6.9]
%APMHR	93 [78–102]
LVEF, %	52 [47–61]
Doppler echo e’ velocity (cm/sec)	7.6 [7.0–9.6]
Delta LVOT VTI CO (L/min)	1.6 [1.5–1.9]

Data are listed as n (%) or median (interquartile range). Abbreviations: kg/m² Kilograms per meter squared, MCRD Mean cardiac radiation dose, Gy Gray units, mg/L Milligrams per liter, %APMHR Percentage of age-predicted maximal heart rate, LVEF Left-ventricular ejection fraction, e’ Doppler early diastolic mitral annular velocity, cm/sec Centimeters per second, LVOT VTI CO Left-ventricular outflow tract velocity time integral cardiac output with exercise, L/min Liters per minute.

ISSN: 2057-3804